Why AbbVie Stock Soared in September
Any pharmaceutical company as large and sprawling as (NYSE: ABBV) never stops being busy, from pushing investigational drugs along the development pipeline to shipping blockbuster medications to pharmacies.
As in any month, September was eventful for AbbVie. In addition to news about its usual activities, it also scored big with investors because of an important settlement it reached on a key product. Ultimately, over the course of the month, its share price rose by a sturdy 10%.
It's saying something that AbbVie doesn't have just one or two blockbuster drugs in its portfolio, but an entire clutch of them. And one of these was the focus of that pivotal settlement.
Source Fool.com
AbbVie Inc. Stock
€192.60
0.630%
With 37 Buy predictions and not a single Sell prediction AbbVie Inc. is an absolute favorite of our community.
With a target price of 209 € there is a slightly positive potential of 8.52% for AbbVie Inc. compared to the current price of 192.6 €.
